medigraphic.com
Boletín Médico del Hospital Infantil de México

2011, Number 2

<< Back Next >>

Bol Med Hosp Infant Mex 2011; 68 (2)

Achievements and challenges in controlling Chagas disease

Rodríguez-Morales AJ, Von A, Franco-Paredes C

Language: English
References: 91
Page: 101-109
PDF size: 296.73 Kb.


Text Extraction

American trypanosomiasis or Chagas disease continues to endanger the lives of many million people in Latin America, and through travel and population migration there is a risk of congenital cases in nonendemic settings. Substantial improvements in the transmission of the disease have been achieved through vector control and blood-bank screening. However, vector-borne transmission remains the main mode of acquisition of infection in many settings coupled with congenital transmission and food-borne and accidental exposure through transplantation or laboratory exposure. The main sites of affection include the heart and gastrointestinal tract. Antiparasitic treatment of indeterminate forms is successful in many cases by delaying the risk of progression of cardiomyopathy, but treatment of chronic chagasic cardiomyopathy remains mainly supportive. The BENEFIT trial that will be completed by late 2011 or early 2012 will provide evidence for or against treating chronic symptomatic forms. Control or eliminating Chagas disease transmission coupled with decreasing the associated burden of disease in Latin America will promote better health and social and economic development among the most impoverished populations in the region.


REFERENCES

  1. World Health Organization Expert Committee on the Control of Chagas Disease. Control of Chagas Disease: Second Report of the WHO Expert Committee. Brasilia: 2000.

  2. Di Noia JM, Buscaglia CA, De Marchi CR, Almeida IC, Frasch AC. A Trypanosoma cruzi small surface molecule provides the first immunological evidence that Chagas’ disease is due to a single parasite lineage. J Exp Med 2002;195:401-413.

  3. Fernandes O, Souto RP, Castro JA, Pereira JB, Fernandes NC, Junqueira ACV, et al. Brazilian isolates of Trypanosoma cruzi from humans and triatomines classified into two lineages using mini-exon and ribosomal RNA sequences. Am J Trop Med Hyg 1998;58:807-811.

  4. Trypanosoma cruzi Genome Consortium. The Trypanosoma cruzi genome initiative. Parasitol Today 1997;13:16-22.

  5. Atwood JA, Weatherly DB, Minning TA, Bundy B, Cavola C, Opperdoes FA, et al. The Trypanosoma cruzi proteome. Science 2005;309:473-476.

  6. Tropical Diseases Research. Seventeenth Programme Report: Making Health Research Work for Poor People, Progress 2003-2004. Geneva: World Health Organization; 2005. pp. 31-33.

  7. Lages-Silva E, Crema E, Ramirez LE, Macedo AM, Pena SD, Chiari E. Relationship between Trypanosoma cruzi and human chagasic megaesophagus: blood and tissue parasitism. Am J Trop Med Hyg 2001;65:435-441.

  8. Chapadeiro E. Clinical evolution and morbi-mortality in Chagas disease. Mem Inst Oswaldo Cruz 1999;94(suppl 1):309-310.

  9. Morel C, Lazdins J. Chagas Disease. Nat Rev Microbiol 2003;1:14-15.

  10. Remme JHF, Feenstra P, Lever PR, Medici A, Morel C, Noma M, et al. Tropical diseases targeted for elimination: Chagas disease, lymphatic filariasis, onchocerciasis, and leprosy. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., eds. Disease Control Priorities in Developing Countries. New York: Oxford University Press; 2006. pp. 433-450.

  11. Kirchhoff LV, Paredes P, Lomelí-Guerrero A, Paredes-Espinoza M, Ron-Guerrero CS, Delgado-Mejia M, et al. Transfusionassociated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States. Transfusion 2006;46:298-304.

  12. Leiby DA, Herron RM, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002;42:549-555.

  13. Leiby DA. Threats to blood safety posed by emerging protozoan pathogens. Vox Sang 2004;87(suppl 2):S120-S122.

  14. Figueiredo JF, Martinez R, da Costa JC, Moysés Neto M, Suaid HJ, Ferraz AS. Transmission of Chagas disease through renal transplantation: report of a case. Trans R Soc Trop Med Hyg 1990;84:61-62.

  15. Centers for Disease Control and Prevention (CDC). Chagas disease after organ transplantationLos Angeles California, 2006. MMWR Morb Mortal Wkly Rep 2006;55:798-800.

  16. Benchimol Barbosa PR. The oral transmission of Chagas’ disease: an acute form of infection responsible for regional outbreaks. Int J Cardiol 2006;112:132-133.

  17. Lambert N, Mehta B, Walters R, Eron JJ. Chagasic encephalitis as the initial manifestation of AIDS. Ann Intern Med 2006;144:941-943.

  18. Ferreira MS. Chagas disease and immunosupression. Mem Inst Oswaldo Cruz 1999;94(suppl 1):325-327.

  19. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001;1:92-100.

  20. Van Voorhis WC, Weller PF. Protozoan infections. In: Federman DD, Dale DC, eds. ACP Medicine; 2006. New York: WebMD Professional Publishing. Available at: http://www.acpmedicine.com/acp/chapters/ch0734.htm

  21. Kirchhoff LV. American trypanosomiasis (Chagas’ disease)a tropical disease now in the United States. N Eng J Med 1993;329:639-644.

  22. Kirchhoff LV. American trypanosomiaisis (Chagas’ Disease). Gastroenterol Clin North Am 1996;25:517-533.

  23. Añez N, Carrasco H, Parada H, Crisante G, Rojas A, Fuenmayor C, et al. Myocardial parasite persistence in chronic chagasic patients. Am J Trop Med Hyg 1999;60:726-732.

  24. Barretto ACP, Ianni BM. The undetermined form of Chagas’ heart disease: concept and forensic implications. São Paulo Med J 1995;113:797-801.

  25. Laranja FS, Dias E, Nobrega G, Miranda, A. Chagas’ disease; a clinical, epidemiologic, and pathologic study. Circulation 1956;14:1035-1060.

  26. Punukollu G, Gowda RM, Khan IA, Navarro VS, Vasavada BC. Clinical aspects of the Chagas’ heart disease. Int J Cardiol 2007;115:279-283.

  27. Bestetti RB, Muccillo G. Clinical course of Chagas’ heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol 1997;60:187-193.

  28. Rassi AJr, Rassi SG, Rassi A. Sudden death in Chagas’ disease. Arq Bras Cardiol 2001;76:86-96.

  29. Camara-Lopes LH. Carcinoma of the esophagus as a complication of megaesophagus. An analysis of seven cases. Am J Dig Dis 1961;6:742-756.

  30. Meneghelli UG. Chagasic enteropathy. Rev Soc Bras Med Trop 2004;37:252-260.

  31. Ferreira MS, Nishioka S, Silvestre MT, Borges AS, Nunes- Araújo FR, Rocha A. Reactivation of Chagas’ disease in patients with AIDS: report of three new cases and review of the literature. Clin Infect Dis 1997;25:1397-1400.

  32. Walker M, Zunt JR. Parasitic central nervous system infections in immunocompromised hosts. Clin Infect Dis 2005;40:1005-1015.

  33. Vaidian A, Weiss L, Tanowitz H. Chagas’ disease and AIDS. Kinetoplastid Biol Dis 2004;3:2.

  34. Milei J, Sánchez J, Storino R, Yu Z, Denduchis B, Ferrans VJ. Antibodies to laminin and immunohistochemical localization of laminin in chronic chagasic cardiomyopathy: a review. Mol Cell Biochem 1993;129:161-170.

  35. Laguens RP, Argel MI, Chambo J, Storino R, Cabeza-Meckert PM. Presence of antiheart and antiskeletal muscle glycolipid autoantibodies in the sera of patients with chagasic cardiopathy. Can J Cardiol 1994;10:769-776.

  36. Arce-Fonseca M, Ballinas-Verdugo MA, Reyes PA, Aranda- Fraustro A, Monteon VM. Autoantibodies to human heart conduction system in Chagas’ disease. Vector Borne Zoonotic Dis 2005;5:233-236.

  37. Smulski C, Labovsky V, Levy G, Hontebeyrie M, Hoebeke J, Levin MJ. Structural basis of the cross-reaction between an antibody to the Trypanosoma cruzi ribosomal P2β protein and human β adrenergic receptor. FASEB J 2006;20:1396-1406.

  38. Gironès N, Rodríguez CI, Carrasco-Marín E, Hernáez RF, de Rego JL, Fresno M. Dominant T- and B-cell epitopes in an autoantigen linked to Chagas’ disease. J Clin Invest 2001;107:985-993.

  39. De Oliveira SF, Pedrosa RC, Nascimento JH, de Carvalho AC, Masuda MO. Sera from chronic chagasic patients with complex cardiac arrhythmias depress electrogenesis and conduction in isolated rabbit hearts. Circulation 1997;96:2031-2037.

  40. Masuda MO, Levin M, De Oliveira SF, Dos Santos Costa PC, Bergami PL, Dos Santos Almeida NA, et al. Functionally active cardiac antibodies in chronic Chagas’ disease are specifically blocked by Trypanosoma cruzi antigens. FASEB J 1998;12:1551-1558.

  41. Kierszenbaum F. Where do we stand on the autoimmunity hypothesis of Chagas disease? Trends Parasitol 2005;21:513-516.

  42. Dos Santos RR, Rossi MA, Laus JL, Silva JS, Savino W, Mengel J. Anti-CD4 abrogates rejection and reestablishes long-term tolerance to syngeneic newborn hearts grafted in mice chronically infected with Trypanosoma cruzi. J Exp Med 1992;175:29-39.

  43. Higuchi ML, Benvenuti LA, Martins Reis M, Metzger M. Pathophysiology of the heart in Chagas’ disease: current status and new developments. Cardiovasc Res 2003;60:96-107.

  44. Gironès N, Fresno M. Etiology of Chagas disease myocarditis: autoimmunity, parasite persistence, or both? Trends Parasitol 2003;19:19-22.

  45. Dávila DF, Donis JH, Torres A, Ferrer JA. A modified and unifying neurogenic hypothesis can explain the natural history of chronic Chagas heart disease. Int J Cardiol 2004;96:191-195.

  46. Monteón-Padilla V, Hernández-Becerril N, Ballinas-Verdugo MA, Aranda-Fraustro A, Reyes PA. Persistence of Trypanosoma cruzi in chronic chagasic cardiopathy patients. Arch Med Res 2001;32:39-43.

  47. Braga MS, Lauria-Pires L, Argañaraz ER, Nascimento RJ, Teixeira AR. Persistent infections in chronic Chagas’ disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop São Paulo 2000;42:157-161.

  48. Olivares-Villagómez D, McCurley TL, Vnencak-Jones CL, Correa-Oliveira R, Colley DG, Carter C. Polymerase chain reaction amplification of three different Trypanosoma cruzi DNA sequences from human chagasic cardiac tissue. Am J Trop Med Hyg 1998;59:563-570.

  49. Higuchi ML, De Brito T, Reis MM, Barbosa A, Bellotti G, Pereira-Barreto AC, Pileggi F. Correlation between Trypanosoma cruzi parasitism and myocardial inflammatory infiltrate in human chronic chagasic myocarditis: light microscopy and immunohistochemical findings. Cardiovasc Pathol 1993;2:101-106.

  50. Palomina SAP, Aiello VD, Higuchi ML. Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and Trypanosoma cruzi antigens. Ann Trop Med Parasitol 2000;94:571-579.

  51. Salomone OA, Juri D, Omelianiuk MA, Sembaj A, Aguerri AM, Carriazo C, et al. Prevalence of circulating Trypanosoma cruzi detected by polymerase chain reaction in patients with Chagas’ cardiomyopathy. Am J Cardiol 2000;85:1274-1276.

  52. Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas’ disease. J Infect Dis 1999;180:480-486.

  53. Viotti R, Vigliano C, Lococo B, Bertocchi B, Petti M, Alvarez MG, Postan M, Armenti A. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006;144:724-734.

  54. Golgher D, Gazzinelli RT. Innate and acquired immunity in the pathogenesis of Chagas disease. Autoimmunity 2004;37:399-409.

  55. Lannes-Vieira J. Trypanosoma cruzi-elicited CD8+ T cellmediated myocarditis: chemokine receptors and adhesion molecules as potential therapeutic targets to control chronic inflammation? Mem Inst Oswaldo Cruz 2003;98:299-304.

  56. Hatcher FM, Kuhn RE, Cerrone MC, Burton RC. Increased natural killer cell activity in experimental american trypanosomiasis. J Immunol 1981;127:1126-1130.

  57. Lieke T, Steeg C, Graefe S, Fleischer B, Jacobs T. Interaction of natural killer cells with Trypanosoma cruzi-infected fibroblasts. Clin Exp Immunol 2006;145:357-364.

  58. Melo RC, Machado CR. Trypanosoma cruzi: peripheral blood monocytes and heart macrophages in the resistance to acute experimental infection in rats. Exp Parasitol 2001;97:15-23.

  59. Minoprio PM, Eisen H, Forni L, D’Imperio-Lima R, Joskowicz M, Coutinho A. Polyclonal lymphocyte responses to murine Trypanosoma cruzi infection. I. Quantitation of both T- and B-cell responses. Scand J Immunol 1986;24:661-668.

  60. Dos Santos PVA, Roffe E, Santiago HC, Torres RA, Marino AP, Paiva CN, et al. Prevalence of CD8+αβ T cells in Trypanosoma cruzi-elicited myocarditis is associated with acquisition of CD62LLowLFA-1HighVLA-4High activation phenotype and expression of IFN-γ-inducible adhesion and chemoattractant molecules. Microbes Infect 2001;3:971-984.

  61. Talvani A, Ribeiro CS, Aliberti JCS, Michailowsky V, Santos PVA, Murta SMF, et al. Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-γ as important determinants of chemokine mRNA expression during infection with Trypanosoma cruzi. Microbes Infect 2000;2:851-866.

  62. Dutra WO, Rocha MOC, Teixeira MM. The clinical immunology of human Chagas disease. Trends Parasitol 2005;21:581-587.

  63. Laucella SA, Postan M, Martin D, Fralish BH, Albareda MC, Alvarez MG, et al. Frequency of interferon-γ-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 2004;189:909-918.

  64. Talvani A, Rocha MO, Barcelos LS, Gomes YM, Ribeiro AL, Teixeira MM. Elevated concentrations of CCL2 and tumor necrosis factor-α in chagasic cardiomyopathy. Clin Infect Dis 2004;38:943-950.

  65. Dutra WO, Gollob KJ, Pinto-Dias JC, Gazzinelli G, Correa-Oliveira R, Coffman RL, et al. Cytokine mRNA profile of peripheral blood mononuclear cells isolated from individuals with Trypanosoma cruzi chronic infection. Scand J Immunol 1997;45:74-80.

  66. Talvani A, Rocha MOC, Ribeiro AL, Correa-Oliveira R, Teixeira MM. Chemokine receptor expression on the surface of peripheral blood mononuclear cells in Chagas disease. J Infect Dis 2004;189:214-220.

  67. Cunha-Neto E, Moliterno R, Coelho V, Guilherme L, Bocchi E, Higuchi ML, et al. Restricted heterogeneity of T cell receptor variable alpha chain transcripts in hearts of Chagas’ disease cardiomyopathy patients. Parasite Immunol 1994;16:171-179.

  68. Menezes CAS, Rocha MOC, Souza PA, Chaves ACL, Gollob KJ, Dutra WO. Phenotypic and functional characteristics of CD28+ and CD28− cells from chagasic patients: distinct repertoire and cytokine expression. Clin Exp Immunol 2004;137:129-138.

  69. Morel CM. Chagas disease, from discovery to controland beyond: history, myths, and lessons to take home. Mem Inst Oswaldo Cruz 1999;94(suppl 1):3-16.

  70. Miles MA. Chagas’ disease (American trypanosomiasis). In: Cohen J, Powderly WG, eds. Infectious Diseases. Edinburgh: Mosby; 2004.

  71. Centers for Disease Control. DPDx, Laboratory Identification of Parasites of Public Health Concern. Trypanosomiasis, American (Trypanosoma cruzi). Available at: http://www.dpd.cdc.gov/dpdx/HTML/TrypanosomiasisAmerican.htm

  72. Da Silveira JF, Umezawa ES, Luquetti AO. Chagas disease: recombinant Trypanosoma cruzi antigens for serological diagnosis. Trends Parasitol 2001;17:286-291.

  73. Coronado X, Zulantay I, Reyes E, Apt W, Venegas J, Rodriguez J, et al. Comparison of Trypanosoma cruzi detection by PCR in blood and dejections of Triatoma infestans fed on patients with chronic Chagas disease. Acta Trop 2006;98:314-317.

  74. Junqueira ACV, Chiari E, Wincker P. Comparison of the polymerase chain reaction with two classical parasitological methods for the diagnosis of Chagas disease in an endemic region of north-eastern Brazil. Trans R Soc Trop Med Hyg 1996;90:129-132.

  75. Salomone OA, Basquiera AL, Sembaj A, Aguerri AM, Reyes ME, Omelianuk M, et al. Trypanosoma cruzi in persons without serologic evidence of disease, Argentina. Emerg Infect Dis 2003;9:1558-1562.

  76. Castro AM, Luquetti AO, Rassi A, Rassi GG, Chiari E, Galvão LMC. Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi. Parasitol Res 2002;88:894-900.

  77. Gomes ML, Galvao LM, Macedo AM, Pena SDJ, Chiari E. Chagas’ disease diagnosis: comparative analysis of parasitologic, molecular, and serologic methods. Am J Trop Med Hyg 1999;60:205-210.

  78. Miller RF. Clinical presentation and significance of emerging opportunistic infections. J Eukaryot Microbiol 2000;47:21-23.

  79. De Castro AM, Luquetti AO, Rassi A, Chiari E, Galvão LMC. Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection. Parasitol Res 2006;99:379-383.

  80. Britto C, Silveira C, Cardoso MA, Marques P, Luquetti A, Macêdo V, et al. Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction. Mem Inst Oswaldo Cruz 2001;96:1-3.

  81. Galvão LMC, Chiari E, Macedo AM, Luquetti AO, Silva SA, Andrade AL. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. J Clin Microbiol 2003;41:5066-5070.

  82. Coura JR, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002;97:3-24.

  83. The Medical Letter. Drugs for Parasitic Infections. Available at: http://secure.medicalletter.org/medicalletter

  84. Paulino M, Iribarne F, Dubin M, Aguilera-Morales S, Tapia O, Stoppani AOM. The chemotherapy of Chagas’ disease: an overview. Mini Rev Med Chem 2005;5:499-519.

  85. Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005;21:508-512.

  86. Urbina JA. Specific treatment of Chagas disease: current status and new developments. Curr Opin Infect Dis 2001;14:733-741.

  87. Hotez PJ, Ferris MT. The antipoverty vaccines. Vaccine 2006;24:5787-5799.

  88. Wrightsman RA, Miller MJ, Saborio JL, Manning JE. Pure paraflagellar rod protein protects mice against Trypanosoma cruzi infection. Infect Immun 1995;63:122-125.

  89. Wizel B, Garg N, Tarleton R. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect Immun 1998;66:5073-5081.

  90. Fralish BH, Tarleton RL. Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine 2003;21:3070-3080.

  91. Scientific Working Group on Chagas disease. Report of the Scientific Working Group on Chagas disease. Buenos Aires: 2005. Available at: http://www.who.int/tdrold/diseases/chagas/swg_chagas.pdf




2020     |     www.medigraphic.com